Impact of metabolic syndrome in surgical patients: Should we bother?

British Journal of Anaesthesia

Volumn 115, Issue 2, 2015, Pages 194-202

  Tzimas, P ^a   Petrou, A ^a   Laou, E ^a   Milionis, H ^a   Mikhailidis, D P ^b   Papadopoulos, G ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

anaesthesia; metabolic syndrome; postoperative outcome; surgical procedures

Indexed keywords

ANESTHETIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANESTHESIA INDUCTION; AORTA VALVE STENOSIS; ATRIAL FIBRILLATION; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; CORONARY ARTERY BYPASS GRAFT; DEEP VEIN THROMBOSIS; DIET THERAPY; DISEASE ASSOCIATION; GENERAL SURGERY; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH SERVICE; HEART INFARCTION; HEART SURGERY; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LUNG DISEASE; LUNG EMBOLISM; MEDLINE; METABOLIC SYNDROME X; MORBIDITY; OBESITY; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; PATIENT CARE; PERIOPERATIVE PERIOD; PHYSICIAN; POSTOPERATIVE COGNITIVE DYSFUNCTION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW; SURGICAL MORTALITY; SURGICAL PATIENT; SURGICAL RISK; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; WOUND INFECTION; ADVERSE EFFECTS; ANESTHESIA; COMPLICATION; MORTALITY; POSTOPERATIVE COMPLICATIONS; PROCEDURES; VASCULAR SURGERY;

ANESTHESIA; ATRIAL FIBRILLATION; BARIATRIC SURGERY; CARDIAC SURGICAL PROCEDURES; HUMANS; METABOLIC SYNDROME X; MORBIDITY; ORTHOPEDIC PROCEDURES; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; VASCULAR SURGICAL PROCEDURES;

EID: 84938573853     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aev199     Document Type: Review

References (108)

1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53
2. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Metabolic syndrome and non-cardiac vascular diseases: an update from human studies. Curr Pharm Des 2013; 20: 4944-52
3. Tung A. Anaesthetic considerations with the metabolic syndrome. Br J Anaesth 2010; 105: Suppl 1: i24-33
4. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52
5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421
6. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association;World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5
7. Athyros VG, Ganotakis ES, Tziomalos K, et al. Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin 2010; 26: 713-9
8. Golden SH, Robinson KA, Saldanha I, Anton B, LadensonPW. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009; 94: 1853-78
9. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28: 629-36
10. Despres JP, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008; 28: 1039-49
11. Turkoglu C, Duman BS, Gunay D, Cagatay P, Ozcan R, Buyukdevrim AS. Effect of abdominal obesity on insulin resistance and the components of the metabolic syndrome: evidence supporting obesity as the central feature. Obes Surg 2003; 13: 699-705
12. Kostapanos MS, Florentin M, Elisaf MS, Mikhailidis DP. Hemostatic factors and the metabolic syndrome. Curr Vasc Pharmacol 2013; 11: 880-905
13. Cullen A, Ferguson A. Perioperative management of the severely obese patient: a selective pathophysiological review. Can J Anaesth 2012; 59: 974-96
14. Oda E. Metabolic syndrome: its history, mechanisms, and limitations. Acta Diabetol 2012; 49: 89-95
15. Echahidi N, Pibarot P, Despres JP, et al. Metabolic syndrome increases operative mortality in patients undergoing coronary artery bypass grafting surgery. J Am Coll Cardiol 2007; 50: 843-51
16. Kajimoto K, Kasai T, Miyauchi K, et al. Metabolic syndrome predicts 10-year mortality in non-diabetic patients following coronary artery bypass surgery. Circ J 2008; 72: 1481-6
17. Guize L, Thomas F, Pannier B, Bean K, Jego B, Benetos A. Allcause mortality associated with specific combinations of the metabolic syndrome according to recent definitions. Diabetes Care 2007; 30: 2381-7
18. Moebus S, Balijepalli C, Lösch C, et al. Age-and sex-specific prevalence and ten-year risk for cardiovascular disease of all 16 risk factor combinations of the metabolic syndrome-a cross-sectional study. Cardiovasc Diabetol 2010; 9: 34
19. Ozyazicioglu A, Yalcinkaya S, Vural AH, Yumun G, Bozkurt O. Effects of metabolic syndrome on early mortality and morbidity in coronary artery bypass graft patients. J Int Med Res 2010; 38: 202-7
20. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28
21. Isomaa B. A major health hazard: the metabolic syndrome. Life Sci 2003; 73: 2395-411
22. Briand M, Lemieux I, Dumesnil JG, et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 2006; 47: 2229-36
23. Briand M, Pibarot P, Despres JP, et al. Metabolic syndrome is associated with faster degeneration of bioprosthetic valves. Circulation 2006; 114 (1 Suppl): I512-7
24. Meyer SR, Suri RM, Wright RS, et al. Does metabolic syndrome influence bioprosthetic mitral valve degeneration and reoperation rate? J Card Surg 2012; 27: 146-51
25. Tadic M, Vukadinovic D, Cvijanovic D, et al. The impact of the metabolic syndrome on the outcome after aortic valve replacement. J Cardiovasc Med (Hagerstown) 2014; 15: 745-51
26. Katz R,Wong ND, Kronmal R, et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 2006; 113: 2113-9
27. Merie C, Kober L, Olsen PS, Andersson C, Jensen JS, Torp-Pedersen C. Risk of stroke after coronary artery bypass grafting: effect of age and comorbidities. Stroke 2012; 43: 38-43
28. Bhayani NH, Hyder O, Frederick W, et al. Effect of metabolic syndrome on perioperative outcomes after liver surgery: a National Surgical Quality Improvement Program (NSQIP) analysis. Surgery 2012; 152: 218-26
29. Pomares J, Palomino R, Gómez CJ, Gómez-Camargo D. Metabolic syndrome and perioperative complications during elective surgery using general anesthesia. Rev Colomb Anestesiol 2012; 40: 106-12
30. Lohsiriwat V, Pongsanguansuk W, Lertakyamanee N, Lohsiriwat D. Impact of metabolic syndrome on the shortterm outcomes of colorectal cancer surgery. Dis Colon Rectum 2010; 53: 186-91
31. Glance LG, Wissler R, Mukamel DB, et al. Perioperative outcomes among patients with the modified metabolic syndrome who are undergoing noncardiac surgery. Anesthesiology 2010; 113: 859-72
32. Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 2014; 35: 2383-431
33. Poldermans D, Bax JJ, Boersma E, et al. Guidelines for preoperative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009; 30: 2769-812
34. Poldermans D, Bax JJ, Boersma E, et al. Guidelines for preoperative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol 2010; 27: 92-137
35. Protack CD, Bakken AM, Xu J, Saad WA, Lumsden AB, Davies MG. Metabolic syndrome: a predictor of adverse outcomes after carotid revascularization. J Vasc Surg 2009; 49: 1172-80
36. Gorter PM, Olijhoek JK, van der Graaf Y, Algra A, Rabelink TJ, Visseren FL. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis 2004; 173: 363-9
37. Smolock CJ, Anaya-Ayala JE, Bismuth J, et al. Impact of metabolic syndrome on the outcomes of superficial femoral artery interventions. J Vasc Surg 2012; 55: 985-93
38. Gandhi R, Razak F, Tso P, Davey JR, Mahomed NN. Metabolic syndrome and the incidence of symptomatic deep vein thrombosis following total knee arthroplasty. J Rheumatol 2009; 36: 2298-301
39. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158: 1525-31
40. Zmistowski B, Dizdarevic I, Jacovides CL, Radcliff KE, Mraovic B, Parvizi J. Patients with uncontrolled components of metabolic syndrome have increased risk of complications following total joint arthroplasty. J Arthroplasty 2013; 28: 904-7
41. Mraovic B, Hipszer BR, Epstein RH, et al. Metabolic syndrome increases risk for pulmonary embolism after hip and knee arthroplasty. Croat Med J 2013; 54: 355-61
42. Gandhi K, Viscusi ER, Schwenk ES, Pulido L, Parvizi J. Quantifying cardiovascular risks in patients with metabolic syndrome undergoing total joint arthroplasty. J Arthroplasty 2012; 27: 514-9
43. Gonzalez Della Valle A, Chiu YL, Ma Y, Mazumdar M, Memtsoudis SG. The metabolic syndrome in patients undergoing knee and hip arthroplasty: trends and in-hospital outcomes in the United States. J Arthroplasty 2012; 27: 1743-9.e1
44. Memtsoudis SG, Kirksey M, Ma Y, et al. Metabolic syndrome and lumbar spine fusion surgery: epidemiology and perioperative outcomes. Spine (Phila Pa 1976) 2012; 37: 989-95
45. Aminian A, Daigle CR, Romero-Talamas H, et al. Risk prediction of complications of metabolic syndrome before and 6 years after gastric bypass. Surg Obes Relat Dis 2014; 10: 576-82
46. Maggard-Gibbons M, Maglione M, Livhits M, et al. Bariatric surgery forweight loss and glycemic control in nonmorbidly obese adults with diabetes: a systematic review. JAMA 2013; 309: 2250-61
47. Neff KJ, le Roux CW. Bariatric surgery: the indications in metabolic disease. Dig Surg 2014; 31: 6-12
48. Purnell JQ, Selzer F, Smith MD, et al. Metabolic syndrome prevalence and associations in a bariatric surgery cohort from the Longitudinal Assessment of Bariatric Surgery-2 study. Metab Syndr Relat Disord 2014; 12: 86-94
49. Bächler T, Schiesser M, Lutz TA, le Roux CW, Bueter M. Where to begin and where to end? Preoperative assessment for patients undergoing metabolic surgery. Dig Surg 2014; 31: 25-32
50. O'Neill T, Allam J. Anaesthetic considerations and management of the obese patient presenting for bariatric surgery. Curr Anaesth Crit Care 2010; 21: 16-23
51. Almassi GH, Schowalter T, Nicolosi AC, et al. Atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg 1997; 226: 501-11
52. Echahidi N, Mohty D, Pibarot P, et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation 2007; 116: I213-9
53. Chamberlain AM, Agarwal SK, Ambrose M, Folsom AR, Soliman EZ, Alonso A. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2010; 159: 850-6
54. Tanner RM, Baber U, Carson AP, et al. Association of the metabolic syndrome with atrial fibrillation among United States adults (from the REasons for Geographic and Racial Differences in Stroke [REGARDS] Study). Am J Cardiol 2011; 108: 227-32
55. Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 1993; 56: 539-49
56. Leitch JW, Thomson D, Baird DK, Harris PJ. The importance of age as a predictor of atrial fibrillation and flutter after coronary artery bypass grafting. J Thorac Cardiovasc Surg 1990; 100: 338-42
57. Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah AS, Habib RH. Obesity and risk of new-onset atrial fibrillation after cardiac surgery. Circulation 2005; 112: 3247-55
58. Leaf A. Plasma nonesterified fatty acid concentration as a risk factor for sudden cardiac death: the Paris Prospective Study. Circulation 2001; 104: 744-5
59. Spach MS, Dolber PC, Heidlage JF. Influence of the passive anisotropic properties on directional differences in propagation following modification of the sodium conductance in human atrial muscle. A model of reentry based on anisotropic discontinuous propagation. Circ Res 1988; 62: 811-32
60. Hurt C, Coisne A, Modine T, et al. Contrasting effects of diabetes and metabolic syndrome on post-operative atrial fibrillation and in-hospital outcome after cardiac surgery. Int J Cardiol 2013; 167: 2347-50
61. Chaney MA, Nikolov MP, Blakeman BP, Bakhos M. Attempting to maintain normoglycemia during cardiopulmonary bypass with insulin may initiate postoperative hypoglycemia. Anesth Analg 1999; 89: 1091-5
62. Donatelli F, Cavagna P, Di Dedda G, et al. Correlation between pre-operative metabolic syndrome and persistent blood glucose elevation during cardiac surgery in non-diabetic patients. Acta Anaesthesiol Scand 2008; 52: 1103-10
63. Wiener RS,Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 2008; 300: 933-44
64. Hudetz JA, Patterson KM, Iqbal Z, Gandhi SD, Pagel PS. Metabolic syndrome exacerbates short-term postoperative cognitive dysfunction in patients undergoing cardiac surgery: results of a pilot study. J Cardiothorac Vasc Anesth 2011; 25: 282-7
65. Hudetz JA, Patterson KM, Amole O, Riley AV, Pagel PS. Postoperative cognitive dysfunction after noncardiac surgery: effects of metabolic syndrome. J Anesth 2011; 25: 337-44
66. Feng X, Degos V, Koch LG, et al. Surgery results in exaggerated and persistent cognitive decline in a rat model of the Metabolic Syndrome. Anesthesiology 2013; 118: 1098-105
67. Sinha AC. Some anesthetic aspects of morbid obesity. Curr Opin Anaesthesiol 2009; 22: 442-6
68. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23
69. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014; 2: 901-10
70. Miller KR, Wischmeyer PE, Taylor B, McClave SA. An evidence-based approach to perioperative nutrition support in the elective surgery patient. JPEN J Parenter Enter Nutr 2013; 37: 39S-50S
71. Cross MB, Yi PH, Thomas CF, Garcia J, Della Valle CJ. Evaluation of malnutrition in orthopaedic surgery. J Am Acad Orthop Surg 2014; 22: 193-9
72. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-609
73. Kotronen A, Westerbacka J, Bergholm R, Pietiläinen KH, Yki-Järvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007; 92: 3490-7
74. Fris RJ. Preoperative low energy diet diminishes liver size. Obes Surg 2004; 14: 1165-70
75. Benjaminov O, Beglaibter N, Gindy L, et al. The effect of a low-carbohydrate diet on the nonalcoholic fatty liver in morbidly obese patients before bariatric surgery. Surg Endosc 2007; 21: 1423-7
76. Sun K, Liu J, Ning G. Active smoking and risk of metabolic syndrome: a meta-analysis of prospective studies. PLoS ONE 2012; 7: e47791
77. WonWY, Lee CU, Chae JH, Kim JJ, Lee C, Kim DJ. Changes of plasma adiponectin levels after smoking cessation. Psychiatry Investig 2014; 11: 173-8
78. Kotani K, Hazama A, Hagimoto A, et al. Adiponectin and smoking status: a systematic review. J Atheroscler Thromb 2012; 19: 787-94
79. Musallam KM, Rosendaal FR, Zaatari G, et al. Smoking and the risk of mortality and vascular and respiratory events in patients undergoing major surgery. JAMA Surg 2013; 148: 755-62
80. Haney M, Löfvenberg R, Svensson O. Optimize perioperative health and begin with insistence on pre-operative smoking cessation. Acta Anaesthesiol Scand 2014; 58: 133-4
81. Ponciano-Rodriguez G, Paez-Martinez N, Villa-Romero A, Gutierrez-Grobe Y, Mendez-Sanchez N. Early changes in the components of the metabolic syndrome in a group of smokers after tobacco cessation. Metab Syndr Relat Disord 2014; 12: 242-50
82. Aronson S, Fontes ML, Miao Y, et al. Risk index for perioperative renal dysfunction/failure: critical dependence on pulse pressure hypertension. Circulation 2007; 115: 733-42
83. Ng JL, Chan MT, Gelb AW. Perioperative stroke in noncardiac, nonneurosurgical surgery. Anesthesiology 2011; 115: 879-90
84. Desai RG, Muntazar M, Goldberg ME. Strategies for managing perioperative hypertension. Curr Hypertens Rep 2009; 11: 173-7
85. Mule G, Calcaterra I, Nardi E, Cerasola G, Cottone S. Metabolic syndrome in hypertensive patients: an unholy alliance. World J Cardiol 2014; 6: 890-907
86. Colberg SR, Sigal RJ, Fernhall B, et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary. Diabetes Care 2010; 33: 2692-6
87. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S76-99
88. Lackland DT, Voeks JH. Metabolic syndrome and hypertension: regular exercise as part of lifestyle management. Curr Hypertens Rep 2014; 16: 492
89. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 2003; 168: 351-8
90. Palomo IG, Gutiérrez CL, Alarcón ML, et al. Increased concentration of plasminogen activator inhibitor-1 and fibrinogen in individuals with metabolic syndrome. Mol Med Rep 2009; 2: 253-7
91. Krysiak R, Gdula-Dymek A, Bachowski R, Okopien B. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes Care 2010; 33: 2266-70
92. Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106: 2442-7
93. Carter AM, Cymbalista CM, Spector TD, Grant PJ, Euro CI. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2007; 27: 2783-9
94. Suehiro A, Wakabayashi I, Uchida K, Yamashita T, Yamamoto J. Impaired spontaneous thrombolytic activity measured by global thrombosis test in males with metabolic syndrome. Thromb Res 2012; 129: 499-501
95. Marckmann P, Toubro S, Astrup A. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects. Eur J Clin Nutr 1998; 52: 329-33
96. Ueba T, Haze T, Sugiyama M, et al. Level, distribution and correlates of platelet-derived microparticles in healthy individuals with special reference to the metabolic syndrome. Thromb Haemost 2008; 100: 280-5
97. Peter K, Myles PS. Perioperative antiplatelet therapy: a knifeedged choice between thrombosis and bleeding still based on consensus rather than evidence. Thromb Haemost 2011; 105: 750-1
98. Capodanno D, Angiolillo DJ. Management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. Circulation 2013; 128: 2785-98
99. ChanWW,Wong GT, Irwin MG. Perioperative statin therapy. Expert Opin Pharmacother 2013; 14: 831-42
100. Fang SY, Roan JN, Luo CY, Tsai YC, Lam CF. Pleiotropic vascular protective effects of statins in perioperative medicine. Acta Anaesthesiol Taiwan 2013; 51: 120-6
101. Singh N, Patel P, Wyckoff T, Augoustides JG. Progress in perioperative medicine: focus on statins. J Cardiothorac Vasc Anesth 2010; 24: 892-6
102. Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol 2014; 31: 517-73
103. Lu CC, Ho ST. Pleiotropic vascular protective effects of statins and anesthetic management. Acta Anaesthesiol Taiwan 2013; 51: 101-2
104. Athyros VG, Tziomalos K, Florentin M, Karagiannis A, Mikhailidis DP. Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect? Curr Med Res Opin 2010; 26: 839-42
105. Paraskevas KI, Liapis CD, Hamilton G, Mikhailidis DP. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery? Eur J Vasc Endovasc Surg 2006; 32: 286-93
106. Kouvelos GN, Arnaoutoglou EM, Matsagkas MI, et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. J Cardiovasc Pharmacol Ther 2013; 18: 5-12
107. Paraskevas KI, Veith FJ, Liapis CD, Mikhailidis DP. Perioperative/periprocedural effects of statin treatment for patients undergoing vascular surgery or endovascular procedures: an update. Curr Vasc Pharmacol 2013; 11: 112-20
108. Mikhailidis DP, Athyros VG. Acute kidney injury: short-term statin therapy for prevention of contrast-induced AKI. Nat Rev Nephrol 2014; 10: 8-9